BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND DNAJB1, HSPF1, 3337, ENSG00000132002, P25685, Hdj1, Hsp40 AND Treatment
20 results:

  • 1. dnajb1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
    Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
    Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. GalNAc-conjugated siRNA targeting the dnajb1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
    Kim J; Kim Y; Lee B
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Successful liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A framework for fibrolamellar carcinoma research and clinical trials.
    Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
    Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the treatment of Patients with Advanced Fibrolamellar Carcinoma.
    Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
    Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. dnajb1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
    Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
    Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1/CDC45 axis.
    Yang S; Ren X; Liang Y; Yan Y; Zhou Y; Hu J; Wang Z; Song F; Wang F; Liao W; Liao W; Ding Y; Liang L
    Oncogene; 2020 Jan; 39(2):249-261. PubMed ID: 31477839
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.
    Tanaka H; Hijioka S; Iwaya H; Mizuno N; Kuwahara T; Okuno N; Ito A; Kuraoka N; Matsumoto S; Obata M; Kurita Y; Yasuda M; Shimizu Y; Kuroda H; Sato Y; Haneda M; Sasaki E; Yatabe Y; Hara K
    Intern Med; 2018 Dec; 57(24):3537-3543. PubMed ID: 30101933
    [TBL] [Abstract] [Full Text] [Related]  

  • 13.
    Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
    Graham RP; Torbenson MS
    Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. FGFR1 and FGFR2 in fibrolamellar carcinoma.
    Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
    Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton.
    Koca İ; Gümüş M; Özgür A; Dişli A; Tutar Y
    Anticancer Agents Med Chem; 2015; 15(7):916-30. PubMed ID: 25846761
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Advances in fibrolamellar hepatocellular carcinoma: a review.
    Lim II; Farber BA; LaQuaglia MP
    Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Correction of cystathionine β-synthase deficiency in mice by treatment with proteasome inhibitors.
    Gupta S; Wang L; Anderl J; Slifker MJ; Kirk C; Kruger WD
    Hum Mutat; 2013 Aug; 34(8):1085-93. PubMed ID: 23592311
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Inhibition of Hsp27 and hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.
    Sharma A; Upadhyay AK; Bhat MK
    Cancer Biol Ther; 2009 Nov; 8(22):2106-13. PubMed ID: 19901540
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Diagnostic imaging and interventional therapy of hepatocellular carcinoma.
    Palma LD
    Br J Radiol; 1998 Aug; 71(848):808-18. PubMed ID: 9828792
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.